Facebook
Linkedin
Tumblr
Twitter
Sign in
My Account
orders
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in / Join
Facebook
Linkedin
Tumblr
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Market Exclusive
My Account
orders
Home
Authors
Posts by ME Staff
ME Staff
47976 POSTS
0 COMMENTS
What Is the Real Cost of AstraZeneca’s Eye Cancer Flop?
ME Staff
-
July 23, 2015
0
Phase III Success Makes this Company a Potential Blockbuster Biotech
ME Staff
-
July 21, 2015
0
Here’s What Markets are Asking About DBV’s Follow Up
ME Staff
-
July 20, 2015
1
This Deal Suggests Biotech Is Far from Its Peak
ME Staff
-
July 16, 2015
1
Anacor Soars; The Two Sides of the Investor Coin
ME Staff
-
July 14, 2015
0
The How, What and When of Semaglutide
ME Staff
-
July 13, 2015
0
Celgene Sees Opportunity in Epizyme, Should We?
ME Staff
-
July 13, 2015
0
IPO Watch: Novartis Majority Held GenSight; Hit or Miss?
ME Staff
-
July 9, 2015
0
What Entresto Means for Novartis
ME Staff
-
July 9, 2015
0
Is the Axovant IPO a Biotech Red Flag?
ME Staff
-
July 7, 2015
0
1
...
4,795
4,796
4,797
4,798
Page 4,796 of 4,798
